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People are taking psychiatric drugs today more than ever throughout North America
and Europe as well as parts of Asia and countries of the global South, reflecting the
way treatment has been affected by the global dominance of biomedicine, sometimes
in seemingly incongruous ways. An anthropological account of this highly
consequential development requires a variety of strategies to explore the nexus of
the subjective experience of psychoactive pharmaceuticals and global processes that
shape psycho-pharmaceutical consumption. A fusion of perspectives is needed since
studies of global processes that address the problem of psychopharmacology often do
not consider the experience of medications for those who take them, while the limited
set of studies of the phenomenology of medication experience has thus far not given
due consideration to the economic and political dimensions of the problem.
In framing the theoretical and clinical contributions of my recent edited volume
addressing this issue. I proposed that our key terms must include the pharmaceutical
self, understood in terms of the subjective experience of psychopharmaceuticals,
and the contemporary pharmaceutical imaginary, understood in terms of the global
shaping of consumption (Jenkins 2011a, b). In the context of the contemporary
global culture of consumption and the arena of global capitalism in which giant
pharmaceutical companies operate, analytic deployment of these terms supports the
recognition that to some extent we are all already pharmaceutical selves. For those
treated for major psychiatric disorders like schizophrenia, these terms help toward
unraveling experiential paradoxes including the frustration of recovery without cure,
the persistence of stigma despite recovery, the blameless guilt of living with a
‘‘biochemical imbalance,’’ the choice of being ‘‘crazy or fat’’ due to medication
effects, and the strained coexistence of pharmaceutical management and psycho-
therapeutic treatment.
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The contributions to this issue of CMP take up the challenge articulated in
Pharmaceutical Self to flesh out the cultural, political, and economic forces that
shape the lived experience and institutional processes of production and circulation
of psychopharmacology worldwide. Schlosser and Hoffer make a vital contribution
to anthropological understanding of the self/imaginary in the use of psychotropic
drugs to include antidepressants, antipsychotics, anxiolytics, and heroin. The social
life of this common yet poorly understood ‘‘cocktail’’ brings into play a complex
moral economy of psychiatric medications (‘‘good drugs’’) and illicit street drugs
(‘‘bad drugs’’). This innovative ethnographic study documents that, as a matter of
lived experience, the circulation of psychotropic knowledge and ingestion creates
personal expertise and conflict in soothing the torment of an unhappy life. The
ethnopsychological and cultural logic of normal/abnormal in this situation sheds
light on what is valued as a matter of routine or ‘steady state.’ The study also
provides first-person accounts of the trouble with drugs, subjectively discerned, as
dulling, transformative, or boring. Calculations of the worth of dampening
unwanted intrusions of voices must be weighed against unwanted weight gain
and loss of one’s customary and valued sense of self. The existential and
phenomenological stakes could not be higher. Kristi Ninnemann’s innovative paper
draws our attention to the critical yet frequently unrecognized verity of biogenetic
variation in metabolic processes and psychopharmaceuticals. Drawing on pioneer-
ing work from ethnopsychopharmacology, she takes a step forward in advancing our
understanding of the ways in which medications are shaped by complicated
interactions among culture, behavioral environment, and biogenetics. This contri-
bution is opportune as a counterbalance to appreciation of the recognition that
culture shapes nearly every aspect of mental illness. Culture is neither the only nor
even the primary source of human variation. The significant matter of individual
variation advanced some 80 years ago by Sapir applies with equal force. Finally, the
paper by Zhiying Ma offers an intriguing if uneven treatment of the pharmaceutical
self and imaginary in China. As also identified by our research group, Ma finds
ambivalence to be central to matters of intimacy, subjectivity, and the treatment of
mental illness. The cadence of ambivalence and paradox in the emergence of the
pharmaceutical self come together in this set of papers to make a significant
contribution to a newly emerging anthropological spotlight on the reciprocal
shaping of lived experience and institutional forces of globalization.
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